<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01640925</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00006876</org_study_id>
    <secondary_id>1211-0239</secondary_id>
    <nct_id>NCT01640925</nct_id>
  </id_info>
  <brief_title>Trial of 2% Chlorhexidine Bathing on Nosocomial Infections in the Surgical Intensive Care Unit</brief_title>
  <official_title>Randomized Controlled Trial of 2% Chlorhexidine Bathing on Nosocomial Infections in the Surgical Intensive Care Unit</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joshua Swan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Texas Southern University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Methodist Hospital System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Methodist Hospital System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective, randomized, controlled trial will compare the incidence of nosocomial
      infections (composite of primary bloodstream infections, catheter-associated urinary tract
      infections, ventilator-associated pneumonia, and surgical site infections) that occur in
      intensive care unit (ICU) patients bathed with 2% chlorhexidine solution versus patients who
      receive standard bathing (soap and water or non-medicated cloths).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Upon study enrollment, patients will be randomized to one of two study arms. Patients in
      study arm one will receive standard bathing (soap and water or non-medicated cloth) daily.
      Patients in study arm two will receive a 2% chlorhexidine bath on study day 1 and every 48
      hours and a standard bath (soap and water or non-medicated cloths) on study day 2 and every
      48 hours. Patients will be followed until ICU day 28 or discharged from the surgical ICU.

      Hypothesis: Compared to standard daily bathing, chlorhexidine-based bathing on ICU admission
      and every 48 hours will decrease the incidence of nosocomial infections.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Nosocomial Infection</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Proportion of patients with one or more incident nosocomial infections.
Primary Efficacy Endpoints* (Composite of new nosocomial infection)
Primary Bloodstream Infection
Catheter Related Urinary Tract Infection
Ventilator-Associated Pneumonia**
Surgical Site Infection
(*)Diagnosed using the Centers for Disease Control criteria for hospital acquired infections. Only infections that develop 48 hours or more after study enrollment will be counted as primary endpoints.
(**)Ventilator associated pneumonia is defined as pneumonia that developed after 48 hours of mechanical ventilation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Skin Irritation</measure>
    <time_frame>up to 28 days</time_frame>
    <description>The incidence of new onset skin irritation will be recorded and graded for severity using the National Cancer Institute Common Terminology Criteria for Adverse Events v4.03.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU Length of Stay in Days</measure>
    <time_frame>up to 28 days</time_frame>
    <description>Number of days in the ICU after enrollment in study until first ICU discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With In-hospital Mortality</measure>
    <time_frame>up to 28 days or until first hospital discharge</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">350</enrollment>
  <condition>Cross Infection</condition>
  <condition>Pneumonia, Ventilator-associated</condition>
  <condition>Catheter-related Infections</condition>
  <condition>Infection Due to Indwelling Urinary Catheter</condition>
  <condition>Surgical Wound Infection</condition>
  <arm_group>
    <arm_group_label>Chlorhexidine gluconate bathing</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Upon study enrollment, patients will be bathed with a 2% chlorhexidine gluconate solution on study day 1 and every 48 hours until study completion. The patient will be bathed using standard bathing (non-medicated cloths or soap and water) on study day 2 and every 48 hours after that.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard bathing</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Upon study enrollment, patients will be bathed using standard bathing (non-medicated cloths or soap and water) daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chlorhexidine gluconate</intervention_name>
    <description>Chlorhexidine gluconate 2% solution applied topically for full body bathing once every 48 hours</description>
    <arm_group_label>Chlorhexidine gluconate bathing</arm_group_label>
    <other_name>Bactoshield 4%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard bathing</intervention_name>
    <description>The patient will be bathed using standard bathing (non-medicated cloths or soap and water) daily.</description>
    <arm_group_label>Standard bathing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Admission to the surgical intensive care unit at The Methodist Hospital (Houston, TX)

          -  Anticipated surgical intensive care unit length of stay of 48 hours or more

        Exclusion Criteria:

          -  Pregnancy

          -  Age less than 18 years old

          -  Braden score of less than 9 upon admission to the surgical intensive care unit

          -  Known allergy to chlorhexidine gluconate

          -  Active skin irritation upon admission to the surgical intensive care unit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joshua T Swan, Pharm.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Methodist Hospital, Texas Southern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Surgical Intensive Care Unit, The Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Swan JT, Bui LN, Pham VP, Shirkey BA, Graviss EA, Hai SA, Ashton CM, Wray NP. &quot;RCT of chlorhexidine versus soap &amp; water bathing for prevention of hospital-acquired infections in SICU&quot;. Critical Care Medicine. 2014;42(12 supplement):abstract 4.</citation>
  </results_reference>
  <results_reference>
    <citation>Swan JT, Ashton CM, Bui LN, Pham VP, Shirkey BA, Blackshear JE, Bersamin JB, Pomer RM, Johnson ML, Magtoto AD, Butler MO, Tran SK, Sanchez LR, Patel JG, Ochoa RA Jr, Hai SA, Denison KI, Graviss EA, Wray NP. Effect of Chlorhexidine Bathing Every Other Day on Prevention of Hospital-Acquired Infections in the Surgical ICU: A Single-Center, Randomized Controlled Trial. Crit Care Med. 2016 Oct;44(10):1822-32. doi: 10.1097/CCM.0000000000001820.</citation>
    <PMID>27428384</PMID>
  </results_reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 5, 2012</study_first_submitted>
  <study_first_submitted_qc>July 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2012</study_first_posted>
  <results_first_submitted>April 15, 2015</results_first_submitted>
  <results_first_submitted_qc>May 4, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 22, 2015</results_first_posted>
  <last_update_submitted>March 27, 2018</last_update_submitted>
  <last_update_submitted_qc>March 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The Methodist Hospital System</investigator_affiliation>
    <investigator_full_name>Joshua Swan</investigator_full_name>
    <investigator_title>Sponsor-Investigator/Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>nosocomial infection</keyword>
  <keyword>hospital acquired infection</keyword>
  <keyword>chlorhexidine</keyword>
  <keyword>pneumonia, ventilator-associated</keyword>
  <keyword>catheter-related infections</keyword>
  <keyword>urinary tract infections, catheter-related</keyword>
  <keyword>surgical site infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Wound Infection</mesh_term>
    <mesh_term>Surgical Wound</mesh_term>
    <mesh_term>Cross Infection</mesh_term>
    <mesh_term>Surgical Wound Infection</mesh_term>
    <mesh_term>Catheter-Related Infections</mesh_term>
    <mesh_term>Pneumonia, Ventilator-Associated</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chlorhexidine</mesh_term>
    <mesh_term>Chlorhexidine gluconate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Plan to share data to be determined.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Chlorhexidine Gluconate Bathing</title>
          <description>Upon study enrollment, patients will be bathed with a 2% chlorhexidine gluconate solution on study day 1 and every 48 hours until study completion. The patient will be bathed using standard bathing (non-medicated cloths or soap and water) on study day 2 and every 48 hours after that.
Chlorhexidine gluconate: Chlorhexidine gluconate 2% solution applied topically for full body bathing once every 48 hours</description>
        </group>
        <group group_id="P2">
          <title>Standard Bathing</title>
          <description>Upon study enrollment, patients will be bathed using standard bathing (non-medicated cloths or soap and water) daily.
Standard bathing: The patient will be bathed using standard bathing (non-medicated cloths or soap and water) daily.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="175"/>
                <participants group_id="P2" count="175"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="161"/>
                <participants group_id="P2" count="164"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Previously enrolled in this trial</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Chlorhexidine Gluconate Bathing</title>
          <description>Upon study enrollment, patients will be bathed with a 2% chlorhexidine gluconate solution on study day 1 and every 48 hours until study completion. The patient will be bathed using standard bathing (non-medicated cloths or soap and water) on study day 2 and every 48 hours after that.
Chlorhexidine gluconate: Chlorhexidine gluconate 2% solution applied topically for full body bathing once every 48 hours</description>
        </group>
        <group group_id="B2">
          <title>Standard Bathing</title>
          <description>Upon study enrollment, patients will be bathed using standard bathing (non-medicated cloths or soap and water) daily.
Standard bathing: The patient will be bathed using standard bathing (non-medicated cloths or soap and water) daily.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="161"/>
            <count group_id="B2" value="164"/>
            <count group_id="B3" value="325"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.4" spread="15.9"/>
                    <measurement group_id="B2" value="60.2" spread="16.5"/>
                    <measurement group_id="B3" value="59.8" spread="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="141"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Nosocomial Infection</title>
        <description>Proportion of patients with one or more incident nosocomial infections.
Primary Efficacy Endpoints* (Composite of new nosocomial infection)
Primary Bloodstream Infection
Catheter Related Urinary Tract Infection
Ventilator-Associated Pneumonia**
Surgical Site Infection
(*)Diagnosed using the Centers for Disease Control criteria for hospital acquired infections. Only infections that develop 48 hours or more after study enrollment will be counted as primary endpoints.
(**)Ventilator associated pneumonia is defined as pneumonia that developed after 48 hours of mechanical ventilation.</description>
        <time_frame>Up to 28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Chlorhexidine Gluconate Bathing</title>
            <description>Upon study enrollment, patients will be bathed with a 2% chlorhexidine gluconate solution on study day 1 and every 48 hours until study completion. The patient will be bathed using standard bathing (non-medicated cloths or soap and water) on study day 2 and every 48 hours after that.
Chlorhexidine gluconate: Chlorhexidine gluconate 2% solution applied topically for full body bathing once every 48 hours</description>
          </group>
          <group group_id="O2">
            <title>Standard Bathing</title>
            <description>Upon study enrollment, patients will be bathed using standard bathing (non-medicated cloths or soap and water) daily.
Standard bathing: The patient will be bathed using standard bathing (non-medicated cloths or soap and water) daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Nosocomial Infection</title>
          <description>Proportion of patients with one or more incident nosocomial infections.
Primary Efficacy Endpoints* (Composite of new nosocomial infection)
Primary Bloodstream Infection
Catheter Related Urinary Tract Infection
Ventilator-Associated Pneumonia**
Surgical Site Infection
(*)Diagnosed using the Centers for Disease Control criteria for hospital acquired infections. Only infections that develop 48 hours or more after study enrollment will be counted as primary endpoints.
(**)Ventilator associated pneumonia is defined as pneumonia that developed after 48 hours of mechanical ventilation.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
                <count group_id="O2" value="164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The number of patients needed to achieve 80% power was estimated at 171 using Cox proportional hazards regression (hazard ratio reduction of 0.66; 0.15 probability of infection with control) using a two-sided 5% significance.</non_inferiority_desc>
            <p_value>0.049</p_value>
            <method>Regression, Cox</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.555</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.309</ci_lower_limit>
            <ci_upper_limit>0.998</ci_upper_limit>
            <estimate_desc>Hypothesis: Compared to soap and water daily bathing, 2% chlorhexidine gluconate bathing on ICU admission and every 48 hours during surgical ICU care will decrease the risk of acquiring four hospital-acquired infections in surgical ICU patients.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Skin Irritation</title>
        <description>The incidence of new onset skin irritation will be recorded and graded for severity using the National Cancer Institute Common Terminology Criteria for Adverse Events v4.03.</description>
        <time_frame>up to 28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Chlorhexidine Gluconate Bathing</title>
            <description>Upon study enrollment, patients will be bathed with a 2% chlorhexidine gluconate solution on study day 1 and every 48 hours until study completion. The patient will be bathed using standard bathing (non-medicated cloths or soap and water) on study day 2 and every 48 hours after that.
Chlorhexidine gluconate: Chlorhexidine gluconate 2% solution applied topically for full body bathing once every 48 hours</description>
          </group>
          <group group_id="O2">
            <title>Standard Bathing</title>
            <description>Upon study enrollment, patients will be bathed using standard bathing (non-medicated cloths or soap and water) daily.
Standard bathing: The patient will be bathed using standard bathing (non-medicated cloths or soap and water) daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Skin Irritation</title>
          <description>The incidence of new onset skin irritation will be recorded and graded for severity using the National Cancer Institute Common Terminology Criteria for Adverse Events v4.03.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
                <count group_id="O2" value="164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ICU Length of Stay in Days</title>
        <description>Number of days in the ICU after enrollment in study until first ICU discharge.</description>
        <time_frame>up to 28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Chlorhexidine Gluconate Bathing</title>
            <description>Upon study enrollment, patients will be bathed with a 2% chlorhexidine gluconate solution on study day 1 and every 48 hours until study completion. The patient will be bathed using standard bathing (non-medicated cloths or soap and water) on study day 2 and every 48 hours after that.
Chlorhexidine gluconate: Chlorhexidine gluconate 2% solution applied topically for full body bathing once every 48 hours</description>
          </group>
          <group group_id="O2">
            <title>Standard Bathing</title>
            <description>Upon study enrollment, patients will be bathed using standard bathing (non-medicated cloths or soap and water) daily.
Standard bathing: The patient will be bathed using standard bathing (non-medicated cloths or soap and water) daily.</description>
          </group>
        </group_list>
        <measure>
          <title>ICU Length of Stay in Days</title>
          <description>Number of days in the ICU after enrollment in study until first ICU discharge.</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
                <count group_id="O2" value="164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" spread="11.4"/>
                    <measurement group_id="O2" value="7.0" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With In-hospital Mortality</title>
        <time_frame>up to 28 days or until first hospital discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Chlorhexidine Gluconate Bathing</title>
            <description>Upon study enrollment, patients will be bathed with a 2% chlorhexidine gluconate solution on study day 1 and every 48 hours until study completion. The patient will be bathed using standard bathing (non-medicated cloths or soap and water) on study day 2 and every 48 hours after that.
Chlorhexidine gluconate: Chlorhexidine gluconate 2% solution applied topically for full body bathing once every 48 hours</description>
          </group>
          <group group_id="O2">
            <title>Standard Bathing</title>
            <description>Upon study enrollment, patients will be bathed using standard bathing (non-medicated cloths or soap and water) daily.
Standard bathing: The patient will be bathed using standard bathing (non-medicated cloths or soap and water) daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With In-hospital Mortality</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
                <count group_id="O2" value="164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Chlorhexidine Gluconate Bathing</title>
          <description>Upon study enrollment, patients will be bathed with a 2% chlorhexidine gluconate solution on study day 1 and every 48 hours until study completion. The patient will be bathed using standard bathing (non-medicated cloths or soap and water) on study day 2 and every 48 hours after that.
Chlorhexidine gluconate: Chlorhexidine gluconate 2% solution applied topically for full body bathing once every 48 hours</description>
        </group>
        <group group_id="E2">
          <title>Standard Bathing</title>
          <description>Upon study enrollment, patients will be bathed using standard bathing (non-medicated cloths or soap and water) daily.
Standard bathing: The patient will be bathed using standard bathing (non-medicated cloths or soap and water) daily.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>NCI CTCAE v4.03</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 3 Adverse Skin Occurence</sub_title>
                <description>One severe (grade 3) skin occurrence was detected in the chlorhexidine arm; however, a blinded reviewer determined that this was due to an allergic reaction to a systemic penicillin antibiotic and was not related to full-body bathing.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>NCI CTCAE v4.03</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Incident adverse skin occurrence</sub_title>
                <counts group_id="E1" events="43" subjects_affected="30" subjects_at_risk="161"/>
                <counts group_id="E2" events="43" subjects_affected="31" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Joshua Swan</name_or_title>
      <organization>Houston Methodist Hospital</organization>
      <phone>713-441-0165</phone>
      <email>jtswan@houstonmethodist.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

